FindTrial
Sign In

Efficacy of Pre-Treatment with Remimazolam on Prevention of Propofol-Induced Injection Pain in Patients Undergoing abortion

Efficacy of Pre-Treatment with Remimazolam on Prevention of Propofol-Induced Injection Pain in Patients Undergoing abortion

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063794
Enrollment
Unknown
Registered
2022-09-16
Start date
2022-10-15
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

propofol-induced injection pain

Interventions

Group 1 :remimazolam
Group 2:normal saline

Sponsors

Jinan Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 140 patients underwent elective painless abortion examination under general anesthesia, ASA grade I -II; Age is 18-65 years old; BMI is 18-28 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Patients with recent upper respiratory tract infection and asthma; 2. Those who are allergic to benzodiazepines and propofol; 3. Patients with neurological or mental diseases; 4. Those suspected of abusing narcotic analgesics or sedatives; 5. Those who have difficulties in respiratory management.

Design outcomes

Primary

MeasureTime frame
Incidence of propofol injection pain;Adverse reactions;—

Secondary

MeasureTime frame
Propofol injection pain intensity;vital signs;surgery time;recovery time;—

Countries

China

Contacts

Public ContactYuan Ruimei

Jinan Central Hospital; Central Hospital Affiliated to Shandong First Medical University

subave@sina.cn+86 15554127179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026